ArticleHormones & cancer2018
Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER.
Article in Hormones & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 65 citations in OpenAlex.
- Surgical efficiency, safety, and quality of life among four various approaches for T1 stage papillary thyroid carcinoma: a prospective cohort study.Surgical endoscopy · 2026Observational
- Predictive significance of anterior and posterior minimal extrathyroidal extension for central lymph node metastasis in cN0 papillary thyroid carcinoma.Clinical & experimental metastasis · 2026Article
- Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response.Journal of the Endocrine Society · 2026Article
- Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study).European thyroid journal · 2025Observational
- Sex disparities in papillary thyroid cancer survival: Divergent patterns of relative and absolute effects across the age spectrum.PloS one · 2025Article
- Incidence and gender difference of brain metastases in newly diagnosed follicular thyroid cancer patients.European thyroid journal · 2024Article
- Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma.World journal of nuclear medicine · 2024Article
- Course and predictors of excellent response to therapy in patients with differentiated thyroid cancer at long-term follow-up.Saudi medical journal · 2024Article
- An age-and sex-matched postoperative therapy should be required in thyroid papillary carcinoma.Frontiers in endocrinology · 2024Article
- The Sex and Age-Associated Infiltration of B Cells May Result in the Dimorphic Behaviors Observed in Papillary Thyroid Carcinomas.International journal of general medicine · 2024Article
- Association between thyroid cancer and cardiovascular disease: A meta-analysis.Frontiers in cardiovascular medicine · 2023Article
- Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.Frontiers in endocrinology · 2023Article
- NKD2 is correlated with the occurrence, progression and prognosis of thyroid carcinoma.European journal of medical research · 2022Article
- Review
- Long-Term Outcome of Differentiated Thyroid Cancer Patients-Fifty Years of Croatian Thyroid Disease Referral Centre Experience.Diagnostics (Basel, Switzerland) · 2022Article
- A visualized dynamic prediction model for survival of patients with geriatric thyroid cancer: A population-based study.Frontiers in endocrinology · 2022Article
- Hypertension and Obesity: Risk Factors for Thyroid Disease.Frontiers in endocrinology · 2022Article
- Function and Clinical Significance of Circular RNAs in Thyroid Cancer.Frontiers in molecular biosciences · 2022Review
- A machine learning-based approach to predicting the malignant and metastasis of thyroid cancer.Frontiers in oncology · 2022Article
- Sex Bias in Differentiated Thyroid Cancer.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of thyroid cancer in females is significantly higher than that in males; however, females are more likely to have more favorable outcomes. We aimed to determine the characteristics of differentiated thyroid carcinoma (DTC) subtypes in males and females, and to compare their clinical behavior and survival. A total of 68,337 cases were recruited from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. The disease-specific survival (DSS) of follicular variant papillary thyroid carcinoma (FVPTC) and follicular thyroid carcinoma (FTC) were similar to that of classical variant papillary thyroid carcinoma (CPTC) in male patients (FVPTC vs. CPTC, adjusted hazard ratio (aHR) = 0.947, P = 0.776; FTC vs. CPTC, aHR = 1.512, P = 0.104). In premenopausal female (< 55 years old), FVPTC had better DSS than CPTC (aHR = 0.321, P = 0.038) while FTC had worse DSS than CPTC (aHR = 3.272, P = 0.013); in postmenopausal female, FTC had poorer prognosis than CPTC (aHR = 2.145, P = 0.002), no statistical difference was found between CPTC and FVPTC (aHR = 0.724, P = 0.087). For patients younger than 55 years, women had significantly better DSS compared with men with CPTC (aHR = 0.376, P < 0.001) and FVPTC (aHR = 0.102, P < 0.001). However, no difference was observed in patients older than 55 years. Interestingly, outcomes of FTC were not affected by gender in patients of all ages. These results suggested that different clinical behaviors and outcomes of DTC subtypes should be considered in patients with different genders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.